Herpes Simplex Virus Vectors for Gene Transfer to the Central Nervous System
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Neurodegenerative diseases (NDs) have a profound impact on human health worldwide and their incidence is predicted to increase as the population ages. ND severely limits the quality of life and leads to early death. Aside from treatments that may reduce symptoms, NDs are almost completely without means of therapeutic intervention. The genetic and biochemical basis of many NDs is beginning to emerge although most have complex etiologies for which common themes remain poorly resolved. Largely relying on progress in vector design, gene therapy is gaining increasing support as a strategy for genetic treatment of diseases. Here we describe recent developments in the engineering of highly defective herpes simplex virus (HSV) vectors suitable for transfer and long-term expression of large and/or multiple therapeutic genes in brain neurons in the complete absence of viral gene expression. These advanced vector platforms are safe, non-inflammatory, and persist in the nerve cell nucleus for life. In the near term, it is likely that HSV can be used to treat certain NDs that have a well-defined genetic cause. As further information on disease etiology becomes available, these vectors may take on an expanded role in ND therapies, including gene editing and repair.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Self-citationAlzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Inflammation in neurodegenerative diseases
Amor, S., Puentes, F., Baker, D., & Van Der Valk, P. (2010) · Immunology · doi:10.1111/j.1365-2567.2009.03225.x · Cited by 1,355
Apolipoprotein E polymorphism and Alzheimer's disease
Poirier, J., Bertrand, P., Poirier, J., Kogan, S., Gauthier, S., Poirier, J., Gauthier, S., Davignon, J., Bouthillier, D., & Davignon, J. (1993) · The Lancet · doi:10.1016/0140-6736(93)91705-q · Cited by 1,108
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
Gene therapy using adeno-associated virus vectors
Daya, S., & Berns, K. I. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-08 · Cited by 926
Hinderer, C., Katz, N., Buza, E. L., Dyer, C., Goode, T., Bell, P., Richman, L. K., & Wilson, J. M. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.015 · Cited by 814
Mitochondrial Dysfunction in Neurodegenerative Diseases
Johri, A., & Beal, M. F. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.192138 · Cited by 806
Future directions for peptide therapeutics development
Kaspar, A. A., & Reichert, J. M. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.011 · Cited by 750 · cited 1×
“Overall, although peptide carriers show significant promise for the treatment of a multitude of diseases [23], they do not provide cures.”
BackgroundThe genetic epidemiology of neurodegenerative disease
Bertram, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24761 · Cited by 680 · cited 1×
“For example, early-onset AD has been linked to mutations in the genes encoding amyloid precursor protein (APP) and the presenilins (PS-1 and PS-2) involved in amyloid-β processing [3,4], while the ε4 allele of the apolipoprotein E gene has been identified as a risk factor for late-onset AD [8–10].”
BackgroundWirth, T., Parker, N., & Ylä-Herttuala, S. (2013) · Gene · doi:10.1016/j.gene.2013.03.137 · Cited by 607
The epidemiology of frontotemporal dementia
Onyike, C. U., & Diehl-Schmid, J. (2013) · International Review of Psychiatry · doi:10.3109/09540261.2013.776523 · Cited by 543
Adeno-Associated Virus-Based Gene Therapy for CNS Diseases
Hocquemiller, M., Giersch, L., Audrain, M., Parker, S., & Cartier, N. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.087 · Cited by 291 · cited 1×
“7 kb, AAV is among the smallest viruses used for gene therapy and has proven particularly adept at delivery of small gene cassettes (<5 kb) to wide areas of many tissues, including brain [41].”
BackgroundGene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9
Saraiva, J., Nobre, R. J., & Pereira de Almeida, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.09.011 · Cited by 201
Insertional Gene Activation by Lentiviral and Gammaretroviral Vectors
Bokhoven, M., Stephen, S. L., Knight, S., Gevers, E. F., Robinson, I. C., Takeuchi, Y., & Collins, M. K. (2009) · Journal of Virology · doi:10.1128/jvi.01865-08 · Cited by 138
Immune responses to AAV-vectors, the Glybera example from bench to bedside
Ferreira, V., Petry, H., & Salmon, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00082 · Cited by 120 · cited 1×
“The approval of the non-replicative adenoviral vector Gendicine for the treatment of head-and-neck cancer in 2003 [32], the adeno-associated virus (AAV)-derived vector Glybera targeting a lipoprotein lipase deficiency in 2012 [33], and AAV vector-based Luxturna for retinal dystrophy (Lebers congential amaurosis) in 20…”
BackgroundViral and Synthetic RNA Vector Technologies and Applications
Schott, J. W., Morgan, M., Galla, M., & Schambach, A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.143 · Cited by 76 · cited 1×
“Derivatives of many other viruses, including a number of single-stranded RNA viruses [54], are under development as oncolytic vectors [55].”
BackgroundHemophilia gene therapy comes of age
George, L. A. (2017) · Hematology · doi:10.1182/asheducation-2017.1.587 · Cited by 58
Moving toward a gene therapy for Huntington’s disease
Glorioso, J. C., Cohen, J. B., Carlisle, D. L., Munoz-Sanjuan, I., & Friedlander, R. M. (2015) · Gene Therapy · doi:10.1038/gt.2015.102 · Cited by 20
Self-citation
Cited by
Novel approaches for vaccine development
Gebre, M. S., Brito, L. A., Tostanoski, L. H., Edwards, D. K., Carfi, A., & Barouch, D. H. (2021) · Cell · doi:10.1016/j.cell.2021.02.030 · Cited by 347
“Over the past several decades different viruses have been developed into vectors including adenoviruses (Ads) (Barouch and Picker, 2014; Ertl, 2016), cytomegaloviruses (Barouch and Picker, 2014), adeno‐associated viruses (AAV) (Andari and Grimm, 2020), poxviruses (Conrad and Liu, 2019), herpesviruses (Artusi et al., 2…”
Gene Therapy Leaves a Vicious Cycle
Goswami, R., Subramanian, G., Silayeva, L., Newkirk, I., Doctor, D., Chawla, K., Chattopadhyay, S., Chandra, D., Chilukuri, N., & Betapudi, V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00297 · Cited by 347
Gene Therapy Tools for Brain Diseases
Ingusci, S., Verlengia, G., Soukupova, M., Zucchini, S., & Simonato, M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00724 · Cited by 158
Ishikawa, K., & Nakada, K. (2021) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129835 · Cited by 9
Metadata
- Authors
- Artusi, S., Miyagawa, Y., Goins, W. F., Cohen, J. B., & Glorioso, J. C.
- Venue
- Diseases
- Publisher
- MDPI AG
- Published
- 2018-08-14
- Volume
- 6
- Issue
- 3
- Pages
- 74
- ISSN
- 2079-9721 (ISSN-L)
- OpenAlex
- W2886073512
- Cited by
- 59
- References
- 20
- FWCI
- 4.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.